Related Experiment Video
Updated: Sep 25, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
A standardized framework to assess the clinical actionability of genes and associatedconditions for population-based
Background:
As population-based genomic screening (PGS) programs are increasingly implemented, standardized, evidence-based approaches are needed to support decision-making about which genetic findings should be returned based on clinical actionability. The Clinical Genome Resource (ClinGen) Actionability Framework, which guides decision-making on the return of monogenic secondary findings, was adapted to create a framework for the context of PGS in adults.
Methods:
ClinGen convened a group of experts in public health, medical genetics and genomics, genetic counseling, population screening, health economics, and bioethics. Adaptation of the ClinGen Actionability Framework included special considerations for reporting genetic findings in the PGS context, such as screening in unselected populations, penetrance certainty, and cost-effectiveness. Several frameworks relevant to PGS, including public health decision-making and bioethics frameworks, were reviewed and items were abstracted. For items deemed relevant to the PGS context, a thematic clustering method was used to group similar items into conceptually related clusters. Through an iterative process of discussion and consensus building, the clusters were reviewed, refined, and used to define domains of actionability specific to the PGS context. These final domains were selected based on conceptual clarity, distinctiveness, and their relevance to decision-making about the return of genomic findings in unselected populations.
Results:
The ClinGen PGS Actionability Framework includes a set of expanded domains that integrate clinical and public health perspectives on actionability while preserving alignment with the original structure and purpose of the ClinGen AWG framework. The framework guides the review and curation of evidence of actionability for genes and associated conditions, consensus scores for domains of actionability for specific outcome-intervention pairs, and assertions on the level of actionability.
Conclusions:
The ClinGen PGS Actionability Framework provides an evidence-based resource to support clinical communities and decision-makers with policy development on the return of genetic findings in PGS programs.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Genomics